ID   CRYAB_HUMAN             Reviewed;         175 AA.
AC   P02511; B0YIX0; O43416; Q9UC37; Q9UC38; Q9UC39; Q9UC40; Q9UC41;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1990, sequence version 2.
DT   28-JAN-2026, entry version 259.
DE   RecName: Full=Alpha-crystallin B chain;
DE   AltName: Full=Alpha(B)-crystallin;
DE   AltName: Full=Heat shock protein beta-5;
DE            Short=HspB5;
DE   AltName: Full=Heat shock protein family B member 5;
DE   AltName: Full=Renal carcinoma antigen NY-REN-27;
DE   AltName: Full=Rosenthal fiber component;
GN   Name=CRYAB {ECO:0000312|HGNC:HGNC:2389}; Synonyms=CRYA2, HSPB5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   PRELIMINARY PROTEIN SEQUENCE, TISSUE SPECIFICITY, AND ACETYLATION AT MET-1.
RX   PubMed=838078; DOI=10.1016/0014-5793(77)80757-6;
RA   Kramps J.A., de Man B.M., de Jong W.W.;
RT   "The primary structure of the B2 chain of human alpha-crystallin.";
RL   FEBS Lett. 74:82-84(1977).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=2387586; DOI=10.1016/0888-7543(90)90204-8;
RA   Dubin R.A., Ally A.H., Chung S., Piatigorsky J.;
RT   "Human alpha B-crystallin gene and preferential promoter function in
RT   lens.";
RL   Genomics 7:594-601(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1407707; DOI=10.1016/0304-3940(92)90689-5;
RA   Iwaki A., Iwaki T., Goldman J.E., Ogomori K., Tateishi J., Sakaki Y.;
RT   "Accumulation of alpha B-crystallin in brains of patients with Alexander's
RT   disease is not due to an abnormality of the 5'-flanking and coding sequence
RT   of the genomic DNA.";
RL   Neurosci. Lett. 140:89-92(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Yu W., Sarginson J., Gibbs R.A.;
RL   Submitted (JUN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-24; 35-66 AND 118-175, AND ASSOCIATION WITH HSPB1.
RC   TISSUE=Pectoralis muscle;
RX   PubMed=1560006; DOI=10.1016/s0021-9258(18)42574-4;
RA   Kato K., Shinohara H., Goto S., Inaguma Y., Morishita R., Asano T.;
RT   "Copurification of small heat shock protein with alpha B crystallin from
RT   human skeletal muscle.";
RL   J. Biol. Chem. 267:7718-7725(1992).
RN   [11]
RP   PROTEIN SEQUENCE OF 57-66.
RX   PubMed=8999933; DOI=10.1074/jbc.272.4.2268;
RA   Lampi K.J., Ma Z., Shih M., Shearer T.R., Smith J.B., Smith D.L.,
RA   David L.L.;
RT   "Sequence analysis of betaA3, betaB3, and betaA4 crystallins completes the
RT   identification of the major proteins in young human lens.";
RL   J. Biol. Chem. 272:2268-2275(1997).
RN   [12]
RP   PROTEIN SEQUENCE OF 83-89 AND 164-172.
RC   TISSUE=Heart;
RX   PubMed=7498159; DOI=10.1002/elps.11501601192;
RA   Kovalyov L.I., Shishkin S.S., Efimochkin A.S., Kovalyova M.A.,
RA   Ershova E.S., Egorov T.A., Musalyamov A.K.;
RT   "The major protein expression profile and two-dimensional protein database
RT   of human heart.";
RL   Electrophoresis 16:1160-1169(1995).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 107-175.
RX   PubMed=2539261; DOI=10.1016/0092-8674(89)90173-6;
RA   Iwaki T., Kume-Iwaki A., Liem R.K.H., Goldman J.E.;
RT   "Alpha B-crystallin is expressed in non-lenticular tissues and accumulates
RT   in Alexander's disease brain.";
RL   Cell 57:71-78(1989).
RN   [14]
RP   RACEMIZATION/ISOMERIZATION OF SPECIFIC ASP, AND ACETYLATION AT MET-1.
RX   PubMed=8142454; DOI=10.1016/0167-4838(94)90003-5;
RA   Fujii N., Ishibashi Y., Satoh K., Fujino M., Harada K.;
RT   "Simultaneous racemization and isomerization at specific aspartic acid
RT   residues in alpha B-crystallin from the aged human lens.";
RL   Biochim. Biophys. Acta 1204:157-163(1994).
RN   [15]
RP   PHOSPHORYLATION AT SER-19; SER-45 AND SER-59, AND MASS SPECTROMETRY.
RX   PubMed=8175657; DOI=10.1016/s0021-9258(18)99902-3;
RA   Miesbauer L.R., Zhou X., Yang Z., Yang Z., Sun Y., Smith D.L., Smith J.B.;
RT   "Post-translational modifications of water-soluble human lens crystallins
RT   from young adults.";
RL   J. Biol. Chem. 269:12494-12502(1994).
RN   [16]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-cell
RT   carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [17]
RP   MASS SPECTROMETRY, SUSCEPTIBILITY TO OXIDATION, AND PHOSPHORYLATION.
RX   PubMed=10930324; DOI=10.1006/exer.2000.0868;
RA   Hanson S.R.A., Hasan A., Smith D.L., Smith J.B.;
RT   "The major in vivo modifications of the human water-insoluble lens
RT   crystallins are disulfide bonds, deamidation, methionine oxidation and
RT   backbone cleavage.";
RL   Exp. Eye Res. 71:195-207(2000).
RN   [18]
RP   INTERACTION WITH HSPBAP1.
RX   PubMed=10751411; DOI=10.1074/jbc.m001981200;
RA   Liu C., Gilmont R.R., Benndorf R., Welsh M.J.;
RT   "Identification and characterization of a novel protein from Sertoli cells,
RT   PASS1, that associates with mammalian small stress protein hsp27.";
RL   J. Biol. Chem. 275:18724-18731(2000).
RN   [19]
RP   INVOLVEMENT IN CTRCT16.
RX   PubMed=11577372; DOI=10.1086/324158;
RA   Berry V., Francis P., Reddy M.A., Collyer D., Vithana E., MacKay I.,
RA   Dawson G., Carey A.H., Moore A., Bhattacharya S.S., Quinlan R.A.;
RT   "Alpha-B crystallin gene (CRYAB) mutation causes dominant congenital
RT   posterior polar cataract in humans.";
RL   Am. J. Hum. Genet. 69:1141-1145(2001).
RN   [20]
RP   PHOSPHORYLATION AT SER-45 AND SER-59.
RX   PubMed=11158243; DOI=10.1046/j.1471-4159.2001.00038.x;
RA   Kato K., Inaguma Y., Ito H., Iida K., Iwamoto I., Kamei K., Ochi N.,
RA   Ohta H., Kishikawa M.;
RT   "Ser-59 is the major phosphorylation site in alphaB-crystallin accumulated
RT   in the brains of patients with Alexander's disease.";
RL   J. Neurochem. 76:730-736(2001).
RN   [21]
RP   ACETYLATION AT LYS-92.
RX   PubMed=11369851; DOI=10.1110/ps.40901;
RA   Lapko V.N., Smith D.L., Smith J.B.;
RT   "In vivo carbamylation and acetylation of water-soluble human lens alphaB-
RT   crystallin lysine 92.";
RL   Protein Sci. 10:1130-1136(2001).
RN   [22]
RP   INVOLVEMENT IN MFM2A.
RX   PubMed=14681890; DOI=10.1002/ana.10767;
RA   Selcen D., Engel A.G.;
RT   "Myofibrillar myopathy caused by novel dominant negative alpha B-crystallin
RT   mutations.";
RL   Ann. Neurol. 54:804-810(2003).
RN   [23]
RP   INTERACTION WITH TTN.
RX   PubMed=14676215; DOI=10.1074/jbc.m307473200;
RA   Bullard B., Ferguson C., Minajeva A., Leake M.C., Gautel M., Labeit D.,
RA   Ding L., Labeit S., Horwitz J., Leonard K.R., Linke W.A.;
RT   "Association of the chaperone alphaB-crystallin with titin in heart
RT   muscle.";
RL   J. Biol. Chem. 279:7917-7924(2004).
RN   [24]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19464326; DOI=10.1016/j.bbamcr.2009.05.005;
RA   Vos M.J., Kanon B., Kampinga H.H.;
RT   "HSPB7 is a SC35 speckle resident small heat shock protein.";
RL   Biochim. Biophys. Acta 1793:1343-1353(2009).
RN   [25]
RP   SUBUNIT.
RX   PubMed=20836128; DOI=10.1002/iub.373;
RA   Srinivas P., Narahari A., Petrash J.M., Swamy M.J., Reddy G.B.;
RT   "Importance of eye lens alpha-crystallin heteropolymer with 3:1 alphaA to
RT   alphaB ratio: stability, aggregation, and modifications.";
RL   IUBMB Life 62:693-702(2010).
RN   [26]
RP   INVOLVEMENT IN MFM2B.
RX   PubMed=21337604; DOI=10.1002/ana.22331;
RA   Del Bigio M.R., Chudley A.E., Sarnat H.B., Campbell C., Goobie S.,
RA   Chodirker B.N., Selcen D.;
RT   "Infantile muscular dystrophy in Canadian aboriginals is an alphaB-
RT   crystallinopathy.";
RL   Ann. Neurol. 69:866-871(2011).
RN   [27]
RP   ACETYLATION AT LYS-92 AND LYS-166.
RX   PubMed=22120592; DOI=10.1016/j.bbadis.2011.11.011;
RA   Nagaraj R.H., Nahomi R.B., Shanthakumar S., Linetsky M., Padmanabha S.,
RA   Pasupuleti N., Wang B., Santhoshkumar P., Panda A.K., Biswas A.;
RT   "Acetylation of alphaA-crystallin in the human lens: effects on structure
RT   and chaperone function.";
RL   Biochim. Biophys. Acta 1822:120-129(2012).
RN   [28]
RP   SUBUNIT, AND ZINC-BINDING SITES.
RX   PubMed=22890888; DOI=10.1007/s10930-012-9439-0;
RA   Karmakar S., Das K.P.;
RT   "Identification of histidine residues involved in Zn(2+) binding to
RT   alphaA- and alphaB-Crystallin by chemical modification and MALDI TOF mass
RT   spectrometry.";
RL   Protein J. 31:623-640(2012).
RN   [29]
RP   INTERACTION WITH TMEM109.
RX   PubMed=23542032; DOI=10.1016/j.febslet.2013.03.024;
RA   Yamashita A., Taniwaki T., Kaikoi Y., Yamazaki T.;
RT   "Protective role of the endoplasmic reticulum protein mitsugumin23 against
RT   ultraviolet C-induced cell death.";
RL   FEBS Lett. 587:1299-1303(2013).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-59, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   INTERACTION WITH DES.
RX   PubMed=28470624; DOI=10.1007/s12192-017-0788-7;
RA   Sharma S., Conover G.M., Elliott J.L., Der Perng M., Herrmann H.,
RA   Quinlan R.A.;
RT   "alphaB-crystallin is a sensor for assembly intermediates and for the
RT   subunit topology of desmin intermediate filaments.";
RL   Cell Stress Chaperones 22:613-626(2017).
RN   [32]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INVOLVEMENT IN RESTRICTIVE
RP   CARDIOMYOPATHY, VARIANT GLY-109, AND CHARACTERIZATION OF VARIANT GLY-109
RP   AND GLY-120.
RX   PubMed=28493373; DOI=10.1002/humu.23248;
RA   Brodehl A., Gaertner-Rommel A., Klauke B., Grewe S.A., Schirmer I.,
RA   Peterschroeder A., Faber L., Vorgerd M., Gummert J., Anselmetti D.,
RA   Schulz U., Paluszkiewicz L., Milting H.;
RT   "The novel alphaB-crystallin (CRYAB) mutation p.D109G causes restrictive
RT   cardiomyopathy.";
RL   Hum. Mutat. 38:947-952(2017).
RN   [33]
RP   FUNCTION, AND INTERACTION WITH ATP6V1A AND MTOR.
RX   PubMed=31786107; DOI=10.1016/j.bbagen.2019.129496;
RA   Cui X., Feng R., Wang J., Du C., Pi X., Chen D., Li J., Li H., Zhang J.,
RA   Zhang J., Mu H., Zhang F., Liu M., Hu Y.;
RT   "Heat shock factor 4 regulates lysosome activity by modulating the alphaB-
RT   crystallin-ATP6V1A-mTOR complex in ocular lens.";
RL   Biochim. Biophys. Acta 1864:129496-129496(2020).
RN   [34]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH TMED10.
RX   PubMed=32272059; DOI=10.1016/j.cell.2020.03.031;
RA   Zhang M., Liu L., Lin X., Wang Y., Li Y., Guo Q., Li S., Sun Y., Tao X.,
RA   Zhang D., Lv X., Zheng L., Ge L.;
RT   "A Translocation Pathway for Vesicle-Mediated Unconventional Protein
RT   Secretion.";
RL   Cell 181:637-652(2020).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.63 ANGSTROMS) OF 67-157, AND HOMODIMERIZATION.
RX   PubMed=19646995; DOI=10.1016/j.jmb.2009.07.069;
RA   Bagneris C., Bateman O.A., Naylor C.E., Cronin N., Boelens W.C., Keep N.H.,
RA   Slingsby C.;
RT   "Crystal structures of alpha-crystallin domain dimers of alphaB-crystallin
RT   and Hsp20.";
RL   J. Mol. Biol. 392:1242-1252(2009).
RN   [36] {ECO:0007744|PDB:5VVV}
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 38-50 IN COMPLEX WITH OGA,
RP   GLYCOSYLATION AT SER-41, AND DEGLYCOSYLATION AT SER-4.
RX   PubMed=28939839; DOI=10.1038/s41467-017-00865-1;
RA   Li B., Li H., Hu C.W., Jiang J.;
RT   "Structural insights into the substrate binding adaptability and
RT   specificity of human O-GlcNAcase.";
RL   Nat. Commun. 8:666-666(2017).
RN   [37]
RP   VARIANT MFM2A GLY-120, AND INVOLVEMENT IN MFM2A.
RX   PubMed=9731540; DOI=10.1038/1765;
RA   Vicart P., Caron A., Guicheney P., Li Z., Prevost M.-C., Faure A.,
RA   Chateau D., Chapon F., Tome F., Dupret J.-M., Paulin D., Fardeau M.;
RT   "A missense mutation in the alphaB-crystallin chaperone gene causes a
RT   desmin-related myopathy.";
RL   Nat. Genet. 20:92-95(1998).
RN   [38]
RP   CHARACTERIZATION OF VARIANTS MFM2A GLY-120.
RX   PubMed=12601044; DOI=10.1167/iovs.02-0950;
RA   Fu L., Liang J.J.-N.;
RT   "Alteration of protein-protein interactions of congenital cataract
RT   crystallin mutants.";
RL   Invest. Ophthalmol. Vis. Sci. 44:1155-1159(2003).
RN   [39]
RP   VARIANT CMD1II HIS-157, AND INVOLVEMENT IN CMD1II.
RX   PubMed=16483541; DOI=10.1016/j.bbrc.2006.01.154;
RA   Inagaki N., Hayashi T., Arimura T., Koga Y., Takahashi M., Shibata H.,
RA   Teraoka K., Chikamori T., Yamashina A., Kimura A.;
RT   "Alpha B-crystallin mutation in dilated cardiomyopathy.";
RL   Biochem. Biophys. Res. Commun. 342:379-386(2006).
RN   [40]
RP   VARIANT CMD1II SER-154, AND INVOLVEMENT IN CMD1II.
RX   PubMed=16793013; DOI=10.1016/j.bbrc.2006.05.203;
RA   Pilotto A., Marziliano N., Pasotti M., Grasso M., Costante A.M.,
RA   Arbustini E.;
RT   "alphaB-crystallin mutation in dilated cardiomyopathies: low prevalence in
RT   a consecutive series of 200 unrelated probands.";
RL   Biochem. Biophys. Res. Commun. 346:1115-1117(2006).
RN   [41]
RP   VARIANT CTRCT16 THR-171, AND INVOLVEMENT IN CTRCT16.
RX   PubMed=18587492;
RA   Devi R.R., Yao W., Vijayalakshmi P., Sergeev Y.V., Sundaresan P.,
RA   Hejtmancik J.F.;
RT   "Crystallin gene mutations in Indian families with inherited pediatric
RT   cataract.";
RL   Mol. Vis. 14:1157-1170(2008).
RN   [42]
RP   VARIANT CTRCT16 CYS-69, AND INVOLVEMENT IN CTRCT16.
RX   PubMed=21866213;
RA   Sun W., Xiao X., Li S., Guo X., Zhang Q.;
RT   "Mutation analysis of 12 genes in Chinese families with congenital
RT   cataracts.";
RL   Mol. Vis. 17:2197-2206(2011).
RN   [43]
RP   VARIANT MFM2A HIS-109, AND INVOLVEMENT IN MFM2A.
RX   PubMed=21920752; DOI=10.1016/j.nmd.2011.07.004;
RA   Sacconi S., Feasson L., Antoine J.C., Pecheux C., Bernard R., Cobo A.M.,
RA   Casarin A., Salviati L., Desnuelle C., Urtizberea A.;
RT   "A novel CRYAB mutation resulting in multisystemic disease.";
RL   Neuromuscul. Disord. 22:66-72(2012).
RN   [44]
RP   VARIANT MFM2A SER-154, AND INVOLVEMENT IN MFM2A.
RX   PubMed=25208129; DOI=10.1186/s13023-014-0121-9;
RA   Semmler A.L., Sacconi S., Bach J.E., Liebe C., Buermann J., Kley R.A.,
RA   Ferbert A., Anderheiden R., Van den Bergh P., Martin J.J., De Jonghe P.,
RA   Neuen-Jacob E., Mueller O., Deschauer M., Bergmann M., Schroeder J.M.,
RA   Vorgerd M., Schulz J.B., Weis J., Kress W., Claeys K.G.;
RT   "Unusual multisystemic involvement and a novel BAG3 mutation revealed by
RT   NGS screening in a large cohort of myofibrillar myopathies.";
RL   Orphanet J. Rare Dis. 9:121-121(2014).
CC   -!- FUNCTION: May contribute to the transparency and refractive index of
CC       the lens. Has chaperone-like activity, preventing aggregation of
CC       various proteins under a wide range of stress conditions. In lens
CC       epithelial cells, stabilizes the ATP6V1A protein, preventing its
CC       degradation by the proteasome (By similarity).
CC       {ECO:0000250|UniProtKB:P23927}.
CC   -!- SUBUNIT: Heteromer composed of three CRYAA and one CRYAB subunits
CC       (PubMed:20836128). Aggregates with homologous proteins, including the
CC       small heat shock protein HSPB1, to form large heteromeric complexes
CC       (PubMed:10751411). Inter-subunit bridging via zinc ions enhances
CC       stability, which is crucial as there is no protein turn over in the
CC       lens (PubMed:22890888). Interacts with HSPBAP1 and TTN/titin
CC       (PubMed:14676215). Interacts with TMEM109; in the cellular response to
CC       DNA damage (PubMed:23542032). Interacts with DES; binds rapidly during
CC       early stages of DES filament assembly and a reduced binding seen in the
CC       later stages (PubMed:28470624). Interacts with TMED10; the interaction
CC       mediates the translocation from the cytoplasm into the ERGIC
CC       (endoplasmic reticulum-Golgi intermediate compartment) and thereby
CC       secretion (PubMed:32272059). Interacts with ATP6V1A and with MTOR,
CC       forming a ternary complex (PubMed:31786107).
CC       {ECO:0000269|PubMed:10751411, ECO:0000269|PubMed:14676215,
CC       ECO:0000269|PubMed:20836128, ECO:0000269|PubMed:22890888,
CC       ECO:0000269|PubMed:23542032, ECO:0000269|PubMed:28470624,
CC       ECO:0000269|PubMed:31786107, ECO:0000269|PubMed:32272059}.
CC   -!- INTERACTION:
CC       P02511; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-739060, EBI-10173507;
CC       P02511; P09525: ANXA4; NbExp=3; IntAct=EBI-739060, EBI-2556852;
CC       P02511; P05067: APP; NbExp=7; IntAct=EBI-739060, EBI-77613;
CC       P02511; Q6QEF8-4: CORO6; NbExp=3; IntAct=EBI-739060, EBI-10699285;
CC       P02511; Q14194: CRMP1; NbExp=3; IntAct=EBI-739060, EBI-473101;
CC       P02511; P02489: CRYAA; NbExp=20; IntAct=EBI-739060, EBI-6875961;
CC       P02511; P02511: CRYAB; NbExp=30; IntAct=EBI-739060, EBI-739060;
CC       P02511; P05813: CRYBA1; NbExp=2; IntAct=EBI-739060, EBI-7043337;
CC       P02511; P43320: CRYBB2; NbExp=4; IntAct=EBI-739060, EBI-974082;
CC       P02511; P07315: CRYGC; NbExp=5; IntAct=EBI-739060, EBI-6875941;
CC       P02511; P22914: CRYGS; NbExp=2; IntAct=EBI-739060, EBI-11308647;
CC       P02511; P35222: CTNNB1; NbExp=6; IntAct=EBI-739060, EBI-491549;
CC       P02511; O00471: EXOC5; NbExp=3; IntAct=EBI-739060, EBI-949824;
CC       P02511; Q9H8Y8: GORASP2; NbExp=3; IntAct=EBI-739060, EBI-739467;
CC       P02511; Q96LI6-3: HSFY2; NbExp=3; IntAct=EBI-739060, EBI-25830912;
CC       P02511; P04792: HSPB1; NbExp=9; IntAct=EBI-739060, EBI-352682;
CC       P02511; Q16082: HSPB2; NbExp=3; IntAct=EBI-739060, EBI-739395;
CC       P02511; Q3LI64: KRTAP6-1; NbExp=3; IntAct=EBI-739060, EBI-12111050;
CC       P02511; P60891: PRPS1; NbExp=3; IntAct=EBI-739060, EBI-749195;
CC       P02511; Q8WUY3: PRUNE2; NbExp=3; IntAct=EBI-739060, EBI-743880;
CC       P02511; Q3UBX0: Tmem109; Xeno; NbExp=2; IntAct=EBI-739060, EBI-2366300;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19464326,
CC       ECO:0000269|PubMed:28493373}. Nucleus {ECO:0000269|PubMed:19464326}.
CC       Secreted {ECO:0000269|PubMed:32272059}. Lysosome
CC       {ECO:0000250|UniProtKB:P23927}. Note=Translocates to the nucleus during
CC       heat shock and resides in sub-nuclear structures known as SC35 speckles
CC       or nuclear splicing speckles (PubMed:19464326). Localizes at the Z-
CC       bands and the intercalated disk in cardiomyocytes (PubMed:28493373).
CC       Can be secreted; the secretion is dependent on protein unfolding and
CC       facilitated by the cargo receptor TMED10; it results in protein
CC       translocation from the cytoplasm into the ERGIC (endoplasmic reticulum-
CC       Golgi intermediate compartment) followed by vesicle entry and secretion
CC       (PubMed:32272059). {ECO:0000269|PubMed:19464326,
CC       ECO:0000269|PubMed:28493373, ECO:0000269|PubMed:32272059}.
CC   -!- TISSUE SPECIFICITY: Lens as well as other tissues (PubMed:2387586,
CC       PubMed:838078). Expressed in myocardial tissue (PubMed:28493373).
CC       {ECO:0000269|PubMed:2387586, ECO:0000269|PubMed:28493373,
CC       ECO:0000269|PubMed:838078}.
CC   -!- MASS SPECTROMETRY: Mass=20201; Method=Electrospray;
CC       Evidence={ECO:0000269|PubMed:10930324, ECO:0000269|PubMed:8175657};
CC   -!- MASS SPECTROMETRY: Mass=20281; Method=Electrospray; Note=With 1
CC       phosphate group.; Evidence={ECO:0000269|PubMed:10930324,
CC       ECO:0000269|PubMed:8175657};
CC   -!- MASS SPECTROMETRY: Mass=20360; Method=Electrospray; Note=With 2
CC       phosphate groups.; Evidence={ECO:0000269|PubMed:8175657};
CC   -!- MASS SPECTROMETRY: Mass=20199; Method=Electrospray;
CC       Evidence={ECO:0000269|PubMed:10930324, ECO:0000269|PubMed:8175657};
CC   -!- MASS SPECTROMETRY: Mass=20278; Method=Electrospray; Note=With 1
CC       phosphate group.; Evidence={ECO:0000269|PubMed:10930324,
CC       ECO:0000269|PubMed:8175657};
CC   -!- DISEASE: Myopathy, myofibrillar, 2A, adult-onset (MFM2A) [MIM:608810]:
CC       A form of myofibrillar myopathy, a group of chronic neuromuscular
CC       disorders characterized at ultrastructural level by disintegration of
CC       the sarcomeric Z disk and myofibrils, and replacement of the normal
CC       myofibrillar markings by small dense granules, or larger hyaline
CC       masses, or amorphous material. MFM2A is an autosomal dominant form
CC       characterized by weakness of the proximal and distal limb muscles,
CC       weakness of the neck, velopharynx and trunk muscles, respiratory
CC       insufficiency, hypertrophic cardiomyopathy, and cataract.
CC       {ECO:0000269|PubMed:12601044, ECO:0000269|PubMed:14681890,
CC       ECO:0000269|PubMed:21920752, ECO:0000269|PubMed:25208129,
CC       ECO:0000269|PubMed:9731540}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Cataract 16, multiple types (CTRCT16) [MIM:613763]: An
CC       opacification of the crystalline lens of the eye that frequently
CC       results in visual impairment or blindness. Opacities vary in
CC       morphology, are often confined to a portion of the lens, and may be
CC       static or progressive. In general, the more posteriorly located and
CC       dense an opacity, the greater the impact on visual function. CTRCT16
CC       includes posterior polar cataract, among others. Posterior polar
CC       cataract is a subcapsular opacity, usually disk-shaped, located at the
CC       back of the lens. {ECO:0000269|PubMed:11577372,
CC       ECO:0000269|PubMed:18587492, ECO:0000269|PubMed:21866213}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=CRYAB mutations may be involved in restrictive
CC       cardiomyopathy (RCM), a rare non-ischemic myocardial disease. RCM is
CC       characterized by restrictive ventricular-filling physiology in the
CC       presence of normal or reduced diastolic and/or systolic volumes (of 1
CC       or both ventricles), biatrial enlargement, and normal ventricular wall
CC       thickness. {ECO:0000269|PubMed:28493373}.
CC   -!- DISEASE: Myopathy, myofibrillar, 2B, infantile-onset (MFM2B)
CC       [MIM:613869]: A form of myofibrillar myopathy, a group of chronic
CC       neuromuscular disorders characterized at ultrastructural level by
CC       disintegration of the sarcomeric Z disk and myofibrils, and replacement
CC       of the normal myofibrillar markings by small dense granules, or larger
CC       hyaline masses, or amorphous material. MFM2B is an autosomal recessive
CC       form characterized by onset in the first weeks of life after a normal
CC       neonatal period. Affected infants show rapidly progressive muscular
CC       rigidity of the trunk and limbs associated with increasing respiratory
CC       difficulty resulting in death before age 3 years.
CC       {ECO:0000269|PubMed:21337604}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Cardiomyopathy, dilated, 1II (CMD1II) [MIM:615184]: A disorder
CC       characterized by ventricular dilation and impaired systolic function,
CC       resulting in congestive heart failure and arrhythmia. Patients are at
CC       risk of premature death. {ECO:0000269|PubMed:16483541,
CC       ECO:0000269|PubMed:16793013}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the small heat shock protein (HSP20) family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00285}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/40156/CRYAB";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M28638; AAA52104.1; -; Genomic_DNA.
DR   EMBL; S45630; AAB23453.1; -; mRNA.
DR   EMBL; AF007162; AAC19161.1; -; mRNA.
DR   EMBL; AK314029; BAG36739.1; -; mRNA.
DR   EMBL; BT006770; AAP35416.1; -; mRNA.
DR   EMBL; EF444955; ACA05949.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67162.1; -; Genomic_DNA.
DR   EMBL; BC007008; AAH07008.1; -; mRNA.
DR   EMBL; M24906; AAA60267.1; -; mRNA.
DR   CCDS; CCDS8351.1; -.
DR   PIR; A35332; CYHUAB.
DR   RefSeq; NP_001276736.1; NM_001289807.1.
DR   RefSeq; NP_001276737.1; NM_001289808.2.
DR   RefSeq; NP_001355174.1; NM_001368245.1.
DR   RefSeq; NP_001876.1; NM_001885.3.
DR   RefSeq; XP_054223672.1; XM_054367697.1.
DR   PDB; 2KLR; NMR; -; A/B=1-175.
DR   PDB; 2N0K; NMR; -; A/B=64-152.
DR   PDB; 2WJ7; X-ray; 2.63 A; A/B/C/D/E=67-157.
DR   PDB; 2Y1Y; X-ray; 2.00 A; A=71-157.
DR   PDB; 2Y1Z; X-ray; 2.50 A; A/B=67-157.
DR   PDB; 2Y22; X-ray; 3.70 A; A/B/C/D/E/F=67-157.
DR   PDB; 2YGD; EM; 9.40 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=1-175.
DR   PDB; 3J07; Other; -; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=1-175.
DR   PDB; 3L1G; X-ray; 3.32 A; A=68-162.
DR   PDB; 3SGM; X-ray; 1.70 A; A/B/C/D=90-100.
DR   PDB; 3SGN; X-ray; 2.81 A; A/B=90-100.
DR   PDB; 3SGO; X-ray; 2.56 A; A=90-100.
DR   PDB; 3SGP; X-ray; 1.40 A; A/B/C/D=90-100.
DR   PDB; 3SGR; X-ray; 2.17 A; A/B/C/D/E/F=90-100.
DR   PDB; 3SGS; X-ray; 1.70 A; A=95-100.
DR   PDB; 4M5S; X-ray; 1.37 A; A=68-153, B=156-164.
DR   PDB; 4M5T; X-ray; 2.00 A; A/C/E/G=68-153, B/D/F/H=156-164.
DR   PDB; 5VVV; X-ray; 2.80 A; B/D=38-50.
DR   PDB; 6BP9; NMR; -; A/B=64-152.
DR   PDB; 7ROJ; X-ray; 1.60 A; A/B/C/D/E/F/G/H/I/J/K/L=90-100.
DR   PDB; 9BEE; EM; 3.40 A; B=76-163.
DR   PDBsum; 2KLR; -.
DR   PDBsum; 2N0K; -.
DR   PDBsum; 2WJ7; -.
DR   PDBsum; 2Y1Y; -.
DR   PDBsum; 2Y1Z; -.
DR   PDBsum; 2Y22; -.
DR   PDBsum; 2YGD; -.
DR   PDBsum; 3J07; -.
DR   PDBsum; 3L1G; -.
DR   PDBsum; 3SGM; -.
DR   PDBsum; 3SGN; -.
DR   PDBsum; 3SGO; -.
DR   PDBsum; 3SGP; -.
DR   PDBsum; 3SGR; -.
DR   PDBsum; 3SGS; -.
DR   PDBsum; 4M5S; -.
DR   PDBsum; 4M5T; -.
DR   PDBsum; 5VVV; -.
DR   PDBsum; 6BP9; -.
DR   PDBsum; 7ROJ; -.
DR   PDBsum; 9BEE; -.
DR   AlphaFoldDB; P02511; -.
DR   BMRB; P02511; -.
DR   EMDB; EMD-2366; -.
DR   EMDB; EMD-44477; -.
DR   SMR; P02511; -.
DR   BioGRID; 107800; 223.
DR   CORUM; P02511; -.
DR   DIP; DIP-35017N; -.
DR   FunCoup; P02511; 655.
DR   IntAct; P02511; 105.
DR   MINT; P02511; -.
DR   STRING; 9606.ENSP00000433560; -.
DR   BindingDB; P02511; -.
DR   ChEMBL; CHEMBL3621022; -.
DR   MoonDB; P02511; Curated.
DR   TCDB; 8.A.172.1.1; the Alpha-crystallin chaperone (crya) family.
DR   GlyConnect; 33; 1 O-GlcNAc glycan.
DR   GlyCosmos; P02511; 2 sites, 1 glycan.
DR   GlyGen; P02511; 4 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; P02511; -.
DR   MetOSite; P02511; -.
DR   PhosphoSitePlus; P02511; -.
DR   BioMuta; CRYAB; -.
DR   DMDM; 117385; -.
DR   REPRODUCTION-2DPAGE; IPI00021369; -.
DR   jPOST; P02511; -.
DR   MassIVE; P02511; -.
DR   PaxDb; 9606-ENSP00000433560; -.
DR   PeptideAtlas; P02511; -.
DR   PRIDE; P02511; -.
DR   ProteomicsDB; 51527; -.
DR   Pumba; P02511; -.
DR   Antibodypedia; 3674; 1725 antibodies from 49 providers.
DR   CPTC; P02511; 3 antibodies.
DR   DNASU; 1410; -.
DR   Ensembl; ENST00000227251.7; ENSP00000227251.3; ENSG00000109846.10.
DR   Ensembl; ENST00000526180.6; ENSP00000436051.1; ENSG00000109846.10.
DR   Ensembl; ENST00000527899.6; ENSP00000436089.2; ENSG00000109846.10.
DR   Ensembl; ENST00000527950.5; ENSP00000437149.1; ENSG00000109846.10.
DR   Ensembl; ENST00000531198.5; ENSP00000434247.1; ENSG00000109846.10.
DR   Ensembl; ENST00000533475.6; ENSP00000433560.1; ENSG00000109846.10.
DR   Ensembl; ENST00000533879.2; ENSP00000435931.2; ENSG00000109846.10.
DR   Ensembl; ENST00000616970.5; ENSP00000483554.1; ENSG00000109846.10.
DR   Ensembl; ENST00000650687.2; ENSP00000499082.1; ENSG00000109846.10.
DR   Ensembl; ENST00000651164.1; ENSP00000498735.1; ENSG00000109846.10.
DR   GeneID; 1410; -.
DR   KEGG; hsa:1410; -.
DR   MANE-Select; ENST00000650687.2; ENSP00000499082.1; NM_001289808.2; NP_001276737.1.
DR   AGR; HGNC:2389; -.
DR   ClinPGx; PA26907; -.
DR   CTD; 1410; -.
DR   DisGeNET; 1410; -.
DR   GeneCards; CRYAB; -.
DR   HGNC; HGNC:2389; CRYAB.
DR   HPA; ENSG00000109846; Tissue enhanced (heart muscle, skeletal muscle, tongue).
DR   MalaCards; CRYAB; -.
DR   MIM; 123590; gene.
DR   MIM; 608810; phenotype.
DR   MIM; 613763; phenotype.
DR   MIM; 613869; phenotype.
DR   MIM; 615184; phenotype.
DR   OpenTargets; ENSG00000109846; -.
DR   Orphanet; 399058; Alpha-B crystallin-related late-onset myopathy.
DR   Orphanet; 441452; Early-onset lamellar cataract.
DR   Orphanet; 98991; Early-onset nuclear cataract.
DR   Orphanet; 98993; Early-onset posterior polar cataract.
DR   Orphanet; 154; Familial isolated dilated cardiomyopathy.
DR   Orphanet; 280553; Fatal infantile hypertonic myofibrillar myopathy.
DR   VEuPathDB; HostDB:ENSG00000109846; -.
DR   eggNOG; KOG3591; Eukaryota.
DR   GeneTree; ENSGT00940000157434; -.
DR   InParanoid; P02511; -.
DR   OMA; FRDWWED; -.
DR   OrthoDB; 1431247at2759; -.
DR   PAN-GO; P02511; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; P02511; -.
DR   PathwayCommons; P02511; -.
DR   Reactome; R-HSA-3371571; HSF1-dependent transactivation.
DR   SignaLink; P02511; -.
DR   SIGNOR; P02511; -.
DR   Agora; ENSG00000109846; -.
DR   BioGRID-ORCS; 1410; 23 hits in 1155 CRISPR screens.
DR   CD-CODE; 8C2F96ED; Centrosome.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; CRYAB; human.
DR   EvolutionaryTrace; P02511; -.
DR   GeneWiki; CRYAB; -.
DR   GenomeRNAi; 1410; -.
DR   Pharos; P02511; Tchem.
DR   PRO; PR:P02511; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P02511; protein.
DR   Bgee; ENSG00000109846; Expressed in left ventricle myocardium and 205 other cell types or tissues.
DR   ExpressionAtlas; P02511; baseline and differential.
DR   GO; GO:0032432; C:actin filament bundle; IEA:Ensembl.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0097512; C:cardiac myofibril; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0031430; C:M band; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0097060; C:synaptic membrane; IEA:Ensembl.
DR   GO; GO:0030018; C:Z disc; IEA:Ensembl.
DR   GO; GO:0001540; F:amyloid-beta binding; IPI:ARUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008017; F:microtubule binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL.
DR   GO; GO:0005212; F:structural constituent of eye lens; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; IPI:UniProtKB.
DR   GO; GO:0060561; P:apoptotic process involved in morphogenesis; IEA:Ensembl.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IMP:MGI.
DR   GO; GO:0006749; P:glutathione metabolic process; IEA:Ensembl.
DR   GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0031109; P:microtubule polymerization or depolymerization; IEA:Ensembl.
DR   GO; GO:0006936; P:muscle contraction; TAS:ProtInc.
DR   GO; GO:0007517; P:muscle organ development; IEA:Ensembl.
DR   GO; GO:1905907; P:negative regulation of amyloid fibril formation; IDA:ARUK-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:HGNC-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0032387; P:negative regulation of intracellular transport; IDA:HGNC-UCL.
DR   GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:ARUK-UCL.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0006457; P:protein folding; NAS:ProtInc.
DR   GO; GO:0042026; P:protein refolding; IBA:GO_Central.
DR   GO; GO:0050821; P:protein stabilization; IMP:CAFA.
DR   GO; GO:0043067; P:regulation of programmed cell death; IMP:MGI.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0009408; P:response to heat; IBA:GO_Central.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IEA:Ensembl.
DR   GO; GO:0007021; P:tubulin complex assembly; IEA:Ensembl.
DR   CDD; cd06498; ACD_alphaB-crystallin_HspB5; 1.
DR   DisProt; DP00445; -.
DR   FunFam; 2.60.40.790:FF:000011; Alpha-crystallin B chain; 1.
DR   Gene3D; 2.60.40.790; -; 1.
DR   InterPro; IPR002068; A-crystallin/Hsp20_dom.
DR   InterPro; IPR037882; ACD_alphaB-crystallin.
DR   InterPro; IPR055269; Alpha-crystallin/HSP_16.
DR   InterPro; IPR001436; Alpha-crystallin/sHSP_animal.
DR   InterPro; IPR003090; Alpha-crystallin_N.
DR   InterPro; IPR008978; HSP20-like_chaperone.
DR   PANTHER; PTHR45640:SF5; ALPHA-CRYSTALLIN B CHAIN; 1.
DR   PANTHER; PTHR45640; HEAT SHOCK PROTEIN HSP-12.2-RELATED; 1.
DR   Pfam; PF00525; Crystallin; 1.
DR   Pfam; PF00011; HSP20; 1.
DR   PIRSF; PIRSF036514; Sm_HSP_B1; 1.
DR   PRINTS; PR00299; ACRYSTALLIN.
DR   SUPFAM; SSF49764; HSP20-like chaperones; 1.
DR   PROSITE; PS01031; SHSP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cardiomyopathy; Cataract; Chaperone; Cytoplasm;
KW   Direct protein sequencing; Disease variant; Eye lens protein; Glycoprotein;
KW   Lysosome; Metal-binding; Myofibrillar myopathy; Nucleus; Oxidation;
KW   Phosphoprotein; Proteomics identification; Reference proteome; Secreted;
KW   Zinc.
FT   CHAIN           1..175
FT                   /note="Alpha-crystallin B chain"
FT                   /id="PRO_0000125907"
FT   DOMAIN          56..164
FT                   /note="sHSP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00285"
FT   REGION          146..175
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         83
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         104
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000305|PubMed:22890888"
FT   BINDING         106
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         111
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000305|PubMed:22890888"
FT   BINDING         119
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000305|PubMed:22890888"
FT   SITE            48
FT                   /note="Susceptible to oxidation"
FT   SITE            60
FT                   /note="Susceptible to oxidation"
FT   SITE            68
FT                   /note="Susceptible to oxidation"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000269|PubMed:8142454,
FT                   ECO:0000269|PubMed:838078"
FT   MOD_RES         19
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:8175657"
FT   MOD_RES         45
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11158243,
FT                   ECO:0000269|PubMed:8175657"
FT   MOD_RES         59
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11158243,
FT                   ECO:0000269|PubMed:8175657, ECO:0007744|PubMed:24275569"
FT   MOD_RES         92
FT                   /note="N6-acetyllysine; partial"
FT                   /evidence="ECO:0000269|PubMed:11369851,
FT                   ECO:0000269|PubMed:22120592"
FT   MOD_RES         166
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:22120592"
FT   CARBOHYD        41
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000269|PubMed:28939839"
FT   CARBOHYD        170
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000250|UniProtKB:P23928"
FT   VARIANT         41
FT                   /note="S -> Y (in dbSNP:rs2234703)"
FT                   /id="VAR_014607"
FT   VARIANT         51
FT                   /note="P -> L (in dbSNP:rs2234704)"
FT                   /id="VAR_014608"
FT   VARIANT         69
FT                   /note="R -> C (in CTRCT16; uncertain significance;
FT                   dbSNP:rs139750142)"
FT                   /evidence="ECO:0000269|PubMed:21866213"
FT                   /id="VAR_084806"
FT   VARIANT         109
FT                   /note="D -> G (found in patients with restrictive
FT                   cardiomyopathy; likely pathogenic; reduces CRYAB and DES
FT                   localization at the Z-bands and the intercalated disk in
FT                   the myocardium; cytoplasmic aggregations of CRYAB and DES;
FT                   dbSNP:rs1114167341)"
FT                   /evidence="ECO:0000269|PubMed:28493373"
FT                   /id="VAR_079841"
FT   VARIANT         109
FT                   /note="D -> H (in MFM2A; dbSNP:rs387907339)"
FT                   /evidence="ECO:0000269|PubMed:21920752"
FT                   /id="VAR_069528"
FT   VARIANT         120
FT                   /note="R -> G (in MFM2A; decreased interactions with
FT                   wild-type CRYAA and CRYAB but increased interactions with
FT                   wild-type CRYBB2 and CRYGC; cytoplasmic aggregation;
FT                   dbSNP:rs104894201)"
FT                   /evidence="ECO:0000269|PubMed:12601044,
FT                   ECO:0000269|PubMed:28493373, ECO:0000269|PubMed:9731540"
FT                   /id="VAR_007899"
FT   VARIANT         154
FT                   /note="G -> S (in CMD1II and MFM2A; uncertain significance;
FT                   dbSNP:rs150516929)"
FT                   /evidence="ECO:0000269|PubMed:16793013,
FT                   ECO:0000269|PubMed:25208129"
FT                   /id="VAR_070035"
FT   VARIANT         157
FT                   /note="R -> H (in CMD1II; dbSNP:rs141638421)"
FT                   /evidence="ECO:0000269|PubMed:16483541"
FT                   /id="VAR_070036"
FT   VARIANT         171
FT                   /note="A -> T (in CTRCT16; uncertain significance;
FT                   dbSNP:rs370803064)"
FT                   /evidence="ECO:0000269|PubMed:18587492"
FT                   /id="VAR_084807"
FT   CONFLICT        165
FT                   /note="E -> K (in Ref. 4; AAC19161)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        175
FT                   /note="K -> KKMPFLELHFLKQESFPTSE (in Ref. 4; AAC19161)"
FT                   /evidence="ECO:0000305"
FT   STRAND          68..70
FT                   /evidence="ECO:0007829|PDB:4M5S"
FT   STRAND          72..80
FT                   /evidence="ECO:0007829|PDB:4M5S"
FT   STRAND          82..84
FT                   /evidence="ECO:0007829|PDB:2N0K"
FT   HELIX           86..88
FT                   /evidence="ECO:0007829|PDB:4M5S"
FT   STRAND          89..94
FT                   /evidence="ECO:0007829|PDB:4M5S"
FT   STRAND          97..109
FT                   /evidence="ECO:0007829|PDB:4M5S"
FT   STRAND          112..123
FT                   /evidence="ECO:0007829|PDB:4M5S"
FT   TURN            125..127
FT                   /evidence="ECO:0007829|PDB:2KLR"
FT   HELIX           130..132
FT                   /evidence="ECO:0007829|PDB:4M5S"
FT   STRAND          134..137
FT                   /evidence="ECO:0007829|PDB:4M5S"
FT   STRAND          141..148
FT                   /evidence="ECO:0007829|PDB:4M5S"
FT   STRAND          157..159
FT                   /evidence="ECO:0007829|PDB:4M5T"
FT   STRAND          161..163
FT                   /evidence="ECO:0007829|PDB:4M5T"
SQ   SEQUENCE   175 AA;  20159 MW;  AE08BED46B7849CB CRC64;
     MDIAIHHPWI RRPFFPFHSP SRLFDQFFGE HLLESDLFPT STSLSPFYLR PPSFLRAPSW
     FDTGLSEMRL EKDRFSVNLD VKHFSPEELK VKVLGDVIEV HGKHEERQDE HGFISREFHR
     KYRIPADVDP LTITSSLSSD GVLTVNGPRK QVSGPERTIP ITREEKPAVT AAPKK
//
